Study to Evaluate the Safety of the Fixed-dose Combination Rosuvastatin/Ezetimibe for Patients With Dyslipidaemia

NCT04862962 · clinicaltrials.gov ↗

COMPLETED

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Dyslipidemias

Interventions

DRUG: Rosuvastatin 10 or 20mg /Ezetimibe 10 mg Fixed Dose

Sponsor

Laboratorios Silanes S.A. de C.V.